Aktuelle Tagungsinformationen
News and Updates
Anmeldung zur Tagung
Registration
Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Collateral Events
Rahmenprogramm
Social program
Jubiläumsparty
Jubilee Party
DOG Information
DOG Information
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Ausstellerliste
Exhibitors
Sponsoren
Sponsors
Teilnahmegebühren
Registration fees
Impressum
DOG Homepage
Herceptin-therapy in Uveal and Conjunctival Melanoma and in Basal Cell Carcinomas of the Eyelid is not indicated
1Stiemer R. H., 2Vogel U., 1Zierhut M., 1Rohrbach J. M., 2Bültmann B.,
1Eberhard-Karls-Universität Tübingen, Universitäts-Augenklinik, Abt. I (Tübingen)
2Universität Tübingen, Institut für Pathologie (Tübingen)
Purpose: Since the approval of Herceptin®, the promising new therapeutic monoclonal antibody against the external domain of the growth factor receptor HER2/c-erbB2, for therapy in breast cancer, it is of interest whether it can be applied to the therapy of other malignant tumors. However, a strong expression of HER2 on the surface of the tumor cells as well as HLA-A2 of the patient is a prerequisite for the Herceptin® therapy. Therefore, we studied the expression and the genomic status of HER2 in uveal and conjunctival melanoma and in basal cell carcinoma of the eye lid. Additionally we have performed HLA class I and class II typing of patients with basal cell carcinoma of the eye lid and the skin.
Method: Specimens from uveal melanoma (n=5), conjunctival melanoma (n=5) and basal cell carcinoma (n=5), respectively, were fixed in neutral buffered 4% formalin and embedded in paraffin. To assess the immunohistochemical and genomic status of HER2 we used the Dako polyclonal antibody A0485 for immunohistochemistry and the PathVysion-kit (Vysis) for fluorescence in situ hybridization. Immunostaining was scored according to the criteria of the Hercep-Test from Dako. The fluorescence in situ hybridization was evaluated according to the guidelines from Vysis. HLA class I and class II typing was performed on the DNA level isolated from peripheral lymphocytes derived from patients with basal cell carcinoma of the eyelid (n=20) and of the skin (n=10).
Results: No tumor showed a positive expression of HER2. Moreover, the tumor cells displayed a normal genomic status with 2 signals for chromosome 17 and 2 signals for HER2. HLA class I and class II expression was not correlating with the appearance of basal cell carcinoma of the eyelid and the skin.
Conclusions: Herceptin does not seem to be applicable to the therapy of uveal and conjunctival melanoma and basal cell carcinoma of the eye lid.